Molecular Definition Of Filarial And Related Nonfilarial Genes And Proteins

丝虫及相关非丝虫基因和蛋白质的分子定义

基本信息

项目摘要

In the past year we have closed fully genome gaps for Loa loa, W. bancrofti, and S. stercoralis. We now have telomere-to-telemere genomic data for these organisms. We have utilized the genomic data as the backdrop for performing a large number of proteomic and transcriptomic studies. To understand better the developmental programs that underscore the transition between the mosquito-derived infective stage larvae (L3) to mammalian adapted L3s and to L4s following a molt, and the initial week of adaptation to the human host, we adapted an in vitro system that allowed for L3 development and subsequent molting to the L4. Using microarray and proteomic assessments at multiple times through this 9 day process we have not only identified those genes/pathways that are critical for the L3/L4 transition but we have also demonstrated by both pharmacologic inhibition (cysteine protease inhibition) and RNAi (of the critical CPLs) the critical role played by cysteine proteases in the early development of mammalian adapted L3s to L4s. We have recently performed shotgun mass spectroscopy on both human sera of patients with defined filarial infections, excretory/secretory (E/S) products of Loa loa microfilariae, all stages of the O. vovlulus worm, and appropriate controls to identify parasite derived biomarkers of active infection. This has led to identification of molecular targets that have been used d to configure quantitative immunoassays for the rapid detection of active infection for O. volvulus and Loa loa. We have exploited informatic pipelines to identify tandomly and/or interspersed repeats within the genomes of Angiostrongylus cantonensis, Loa loa, Wuchereria bancrofti, Strongyloides stercoralis, T.cruzi, and the various Schistoma spp. We have configured qPCR assays for each of these identified targets and have improved the limits of detection in validated assays. Some of these have been shown to be useful for the diagnosis of these infections in appropriate patient samples. A molecule we termed Brugia malayi IL-5 receptor (IL-5R) binding protein (BmIL5Rbp; also known as Bm8757) was identified from B. malayi filarial worms and found to inhibit human interleukin-5 (IL-5) binding to its human receptor competitively. After the expression and purification of a recombinant BmIL5Rbp and generation of BmIL5Rbp-specific rabbit antibody, we localized the molecule on B. malayi worms through immunohistochemistry and immunoelectron microscopy. RNA interference (RNAi) was used to inhibit BmIL5Rbp mRNA and protein production. BmIL5Rbp was shown to localize to the cuticle of Brugia malayi and to be released in its excretory/secretory products. RNAi inhibited BmIL5Rbp mRNA production by 33%, reduced the surface protein expression by 50%, and suppressed the release of BmIL5Rbp in the excretory/secretory products. RNAi has been used successfully to knock down the mRNA and protein expression of BmIL5Rbp in the early larval stages of B. malayi and provided a proof of principle for the local inhibition of the human IL-5R. These findings provide evidence that a parasite-encoded IL-5R antagonist may locally inhibit a vital host innate immune activation of IL-5 on eosinophils.
在过去的一年里,我们已经完全填补了Loa loa,W。bancrofti和S.粪虫我们现在有这些生物的端粒到端粒的基因组数据。我们利用基因组数据作为背景进行了大量的蛋白质组学和转录组学研究。 为了更好地理解强调蚊子衍生的感染期幼虫(L3)到哺乳动物适应的L3和蜕皮后到L4之间的过渡以及适应人类宿主的最初一周的发育程序,我们适应了允许L3发育和随后蜕皮到L4的体外系统。 通过这9天的过程多次使用微阵列和蛋白质组学评估,我们不仅鉴定了对L3/L4转变至关重要的那些基因/途径,而且我们还通过药理学抑制(半胱氨酸蛋白酶抑制)和RNAi(关键CPL)证明了半胱氨酸蛋白酶在哺乳动物适应性L3至L4的早期发育中所起的关键作用。 我们最近对确定的丝虫感染患者的血清、Loa loa微丝蚴的排泄/分泌(E/S)产物、O. vovlulus蠕虫和适当的对照以鉴定活性感染的寄生虫来源的生物标志物。 这导致了分子靶点的鉴定,这些分子靶点已被用于配置用于快速检测O.肠扭转和Loa loa。 我们已经利用信息管道来识别广州管圆线虫、Loa loa、班氏吴策线虫、粪类圆线虫、T.cruzi和各种血吸虫属的基因组内的重复序列。 我们已经为这些已识别的靶标中的每一种配置了qPCR检测试剂盒,并提高了经验证的检测试剂盒的检测限。 其中一些已被证明是有用的,这些感染的诊断在适当的患者样本。 从B中鉴定出我们称为马来丝虫IL-5受体(IL-5 R)结合蛋白(BmIL 5 Rbp;也称为Bm 8757)的分子。马来蠕虫并发现竞争性抑制人白细胞介素-5(IL-5)与其人受体的结合。在表达和纯化重组BmIL 5 Rbp并制备BmIL 5 Rbp特异性兔抗体后,我们将该分子定位于B。通过免疫组织化学和免疫电子显微镜观察马来蠕虫。RNA干扰(RNAi)抑制BmIL 5 Rbp mRNA和蛋白的产生。BmIL 5 Rbp定位于马来丝虫的表皮,并在其排泄/分泌产物中释放。RNAi抑制BmIL 5 Rbp mRNA的表达33%,表面蛋白的表达减少50%,并抑制排泄/分泌产物中BmIL 5 Rbp的释放。利用RNAi技术成功地抑制了B早期幼虫BmIL 5 Rbp的mRNA和蛋白表达。malayi,并提供了局部抑制人IL-5 R的原理证明。这些发现提供了证据表明,寄生虫编码的IL-5 R拮抗剂可以局部抑制嗜酸性粒细胞上IL-5的重要宿主先天免疫激活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas Nutman其他文献

Thomas Nutman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas Nutman', 18)}}的其他基金

Mali International Center for Excellence in Research: Filariasis
马里国际卓越研究中心:丝虫病
  • 批准号:
    10272144
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Mali International Center for Excellence in Research: Filariasis
马里国际卓越研究中心:丝虫病
  • 批准号:
    8555975
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
India International Center for Excellence in Research
印度国际卓越研究中心
  • 批准号:
    7964701
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Mali International Center for Excellence in Research: Filariasis
马里国际卓越研究中心:丝虫病
  • 批准号:
    8946450
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Immunoregulation /Immune Recognition In Filarial/Nonfilarial Parasitic Infection
丝虫/非丝虫寄生虫感染中的免疫调节/免疫识别
  • 批准号:
    8745274
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
India International Center for Excellence in Research
印度国际卓越研究中心
  • 批准号:
    8336277
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
India International Center for Excellence in Research
印度国际卓越研究中心
  • 批准号:
    10014154
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Mali International Center for Excellence in Research: Filariasis
马里国际卓越研究中心:丝虫病
  • 批准号:
    10692119
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Immunoregulation /Immune Recognition In Filarial/Nonfilarial Parasitic Infection
丝虫/非丝虫寄生虫感染中的免疫调节/免疫识别
  • 批准号:
    10272013
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:
Molecular Definition Of Filarial And Related Nonfilarial Genes And Proteins
丝虫及相关非丝虫基因和蛋白质的分子定义
  • 批准号:
    10272033
  • 财政年份:
  • 资助金额:
    $ 98.73万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 98.73万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 98.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了